ISO 10993-1:2025: Enhanced Characterization, Clearer Risk Logic
The 2025 revision keeps biological evaluation firmly inside ISO 14971 risk management and across the full device life cycle. Your plan-and-report pair matters more than ever: the biological evaluation plan (BEP) must spell out intended use, reasonably foreseeable misuse, categorization, characteristics related to biological safety, hazards and acceptability criteria, gap analysis, strategy, competencies, and responsible personnel; the biological evaluation report (BER) must show conformance to the plan and explain how each biological effect was addressed, including the rationale for test selection or waivers and the overall conclusions on residual biological risk. Evaluations must be revisited when post-market information or product/process changes could affect safety.
ISO 10993-1:2025: Risk Management Integration and Exposure Duration
ISO 10993-1:2025 embeds the biological evaluation within ISO 14971’s risk-management framework. The standard explicitly requires identifying biological hazards, estimating their severity and probability, and comparing residual risk to acceptability criteria. As in risk management, hazard identification is the first step. If a known hazardous constituent is present (at any level), a hazardous situation exists and the risk must be estimated against predefined criteria. Conversely, if no biological hazard can be identified in the device materials or chemicals, then biological risk is essentially zero and no further testing is needed. In practice, every BEP (Biological Evaluation Plan) should trace each identified hazard through risk analysis, risk estimation, and risk controls. For example, a BEP might list a device’s constituent chemicals, known toxicology and clinical history, then assess extractables and leachables against ISO 10993‑17 thresholds to estimate risk. Controls could include changing a material, adding protective barriers, or restricting use to ensure any residual risk meets safety criteria.
Preparing for Biocompatibility Testing: Strategic Considerations for Medical Device Manufacturers
Biocompatibility testing is essential for every medical device, ensuring safety, regulatory approval, and market success. The process, however, can be complex and time-consuming, requiring thorough preparation. By understanding regulatory expectations and engaging with experts early, manufacturers can transform testing from a compliance hurdle into a strategic advantage.
At the European Biomedical Institute (EBI), we support manufacturers in navigating this process with clarity and efficiency, helping them avoid costly delays and strengthen their regulatory submissions.
In Vitro & In Vivo: Strategic Insights for Medical Device Leaders
Biocompatibility testing is not just a regulatory requirement—it is a cornerstone of medical device safety, market approval, and long-term trust. For executives, Quality Managers, and regulatory specialists, understanding in vitro and in vivo testing approaches is crucial for managing risk, meeting ISO 10993 standards, and ensuring smooth regulatory approval.
At the European Biomedical Institute (EBI), we see daily how the right testing strategy can prevent costly delays and accelerate access to market. Both in vitro and in vivo methods are essential, serving different but complementary roles. Recognizing their value from a leadership perspective can transform compliance from a challenge into a strategic advantage.
Biocompatibility Requirements for Wearable Medical Devices: Unique Considerations
Wearable medical devices are transforming healthcare with continuous monitoring, real-time diagnostics, and improved patient engagement. However, their design introduces distinct challenges from a biocompatibility perspective. These devices often involve prolonged skin contact (sometimes can be even long term), contain adhesives and flexible polymers, and are worn in dynamic, moisture-prone environments. Regulatory expectations for biocompatibility evaluation of wearables require special consideration.
Proactive Planning: Combining Biocompatibility with Other Preclinical Testing Needs
Biocompatibility testing is a vital part of preclinical evaluation, but it’s just one piece of the larger puzzle. Manufacturers often face the challenge of aligning multiple testing streams — biocompatibility, electrical safety, performance verification, mechanical integrity, sterilization validation, and more — while meeting tight timelines and regulatory expectations. A fragmented or reactive approach can lead to duplication of effort, missed synergies, and delays. Proactive planning allows manufacturers to optimize resources and timelines while ensuring comprehensive risk management.
Pre-Submission Support: How a Testing Lab Can Help You Prepare for Regulatory Feedback
Pre-submission is a critical phase in medical device development, especially under EU MDR. It’s the point where all your documentation — risk assessments, justifications, test reports — must stand up to Notified Body scrutiny. Many manufacturers underestimate the complexity of this stage. Partnering with a testing lab that goes beyond benchwork and into strategic regulatory support can make a significant difference. This is equally true for FDA submissions, where early engagement can streamline the review process and reduce deficiencies.
How Early Should You Start Thinking About Biocompatibility in Product Development?
In the fast-paced world of medical device innovation, biocompatibility is sometimes treated as an afterthought — a regulatory hurdle addressed just before submission. However, this approach can be risky, costly, and inefficient. Modern regulations like ISO 10993-1 and the EU MDR encourage a lifecycle, risk-based view of biological safety. Integrating biocompatibility considerations early in the product development process is not just smart — it’s essential.
Why a Risk-Based Approach to Biocompatibility Saves You Time and Money
In the realm of medical device development, ensuring biological safety is essential to protect patient health and to comply with regulatory requirements. However, the traditional approach of performing a full battery of biocompatibility tests for every new device iteration is no longer sustainable.
Modern regulatory frameworks, including ISO 10993-1:2023 and the European Medical Device Regulation (MDR 2017/745), endorse a risk-based approach — a strategic, scientific methodology that streamlines biological evaluations without compromising patient safety.
Adopting a risk-based approach can significantly reduce the time and cost associated with market access while maintaining regulatory compliance and scientific credibility.
This article outlines the foundations, implementation strategies, and tangible benefits of a risk-based approach to biocompatibility for medical device manufacturers.
How to Create a Complete Biological Evaluation Report (BER) That Meets Regulatory Expectations
A Biological Evaluation Report (BER) is a cornerstone document in the biological risk assessment process for medical devices. It integrates chemical characterization, toxicological risk assessment, biological testing results, and historical data to present a scientifically justified evaluation of the device’s biological safety. Under the European Medical Device Regulation (MDR 2017/745) and ISO 10993-1:2023, the preparation of a complete and scientifically sound BER is not merely a regulatory formality — it is critical to demonstrating patient safety and device efficacy.
This article outlines the critical elements, structure, and best practices for producing a BER that aligns with global regulatory expectations.